{
    "type": "ETP",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "complex_factors": [
        "Leverage",
        "Swaps",
        "Synthetic replication",
        "Daily reset compounding",
        "Counterparty risk"
    ],
    "classification": "complex",
    "supporting_data": "The WisdomTree EURO STOXX Banks 3x Daily Leveraged product is a fully collateralised, UCITS eligible Exchange Traded Product (ETP) that provides 3x leveraged exposure to the EURO STOXX Banks Daily Leverage 3 EUR Net Return Index. The product uses a fully collateralised swap-based synthetic replication method, confirmed by explicit references to swap agreements and collateral held at The Bank of New York Mellon. The product is not UCITS compliant despite being UCITS eligible, indicating additional complexity. The leverage factor is 3x daily, with daily reset and compounding effects, which can cause returns over periods longer than one day to deviate significantly from the simple 3x multiple of the underlying index. The product carries a highest risk rating of 7/7, indicating very high risk. The KIID and PRIIPs documents highlight significant counterparty risk due to reliance on swap counterparties, collateral management risks, and the potential for total loss of capital. The product is structured as a debt security, not as shares, and involves complex features such as daily leverage reset, compounding, and swap counterparty exposure. The recommended holding period is only 1 day, emphasizing the complexity and risk of holding longer. The product is intended for informed or sophisticated investors with specific knowledge of leveraged and synthetic products. There is no capital protection. The costs include management fees and significant transaction costs related to maintaining the leveraged swap positions. The product\u2019s complexity is driven primarily by its synthetic swap-based replication, use of leverage (3x), daily compounding effects, and counterparty risk exposure. These factors make it difficult for retail investors to understand and manage the risks, fulfilling MiFID II criteria for classification as a complex financial instrument."
}